Limits...
The oncolytic effects of reovirus in canine solid tumor cell lines.

Igase M, Hwang CC, Coffey M, Okuda M, Noguchi S, Mizuno T - J. Vet. Med. Sci. (2015)

Bottom Line: Reovirus has been proven to be a potent oncolytic virus in human medicine.The reovirus-induced cell death occurred via the activation of caspase 3.However, Ras activation was not related to the reovirus-susceptibility in canine solid tumor cell lines, which was similar to reports in canine mast cell tumor and canine lymphoma.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

ABSTRACT
Oncolytic virotherapy is a new strategy for cancer treatment for humans and dogs. Reovirus has been proven to be a potent oncolytic virus in human medicine. Our laboratory has previously reported that canine mast cell tumor and canine lymphoma were susceptible to reovirus. In this study, canine solid tumor cell lines (mammary gland tumor, osteosarcoma and malignant melanoma) were tested to determine their susceptibility towards reovirus. We demonstrated that reovirus induces more than 50% cell death in three canine mammary gland tumors and one canine malignant melanoma cell line. The reovirus-induced cell death occurred via the activation of caspase 3. Ras activation has been shown to be one of the important mechanisms of reovirus-susceptibility in human cancers. However, Ras activation was not related to the reovirus-susceptibility in canine solid tumor cell lines, which was similar to reports in canine mast cell tumor and canine lymphoma. The results of this study highly suggest that canine mammary gland tumor and canine malignant melanoma are also potential candidates for reovirus therapy in veterinary oncology.

No MeSH data available.


Related in: MedlinePlus

Cell viability of canine solid tumor cell lines infected with reovirus. Canine MGT(A), osteosarcoma (B) and malignant melanoma (C) cell lines in triplicate wells weremock-infected or infected with reovirus at MOI 70. After 72 hpi, cell viability wasquantified by trypan blue exclusion test. Mean ± SD, n=3,*P<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4478733&req=5

fig_002: Cell viability of canine solid tumor cell lines infected with reovirus. Canine MGT(A), osteosarcoma (B) and malignant melanoma (C) cell lines in triplicate wells weremock-infected or infected with reovirus at MOI 70. After 72 hpi, cell viability wasquantified by trypan blue exclusion test. Mean ± SD, n=3,*P<0.05.

Mentions: Reovirus-induced cytotoxicity: MTT assay quantifies the inhibition of cellproliferation through the reduction of total mitochondrial activity [32]. In order to examine the reovirus-induced cell death directly, allthe canine solid tumor cell lines were infected with reovirus at MOI 70, which is the titerof virus used for the cytotoxicity assay in mast cell tumor cell lines and lymphoma celllines in our previous report [9, 10], before trypan blue exclusion test was carried out to quantify theproportion of live and dead cells (Fig. 2Fig. 2.


The oncolytic effects of reovirus in canine solid tumor cell lines.

Igase M, Hwang CC, Coffey M, Okuda M, Noguchi S, Mizuno T - J. Vet. Med. Sci. (2015)

Cell viability of canine solid tumor cell lines infected with reovirus. Canine MGT(A), osteosarcoma (B) and malignant melanoma (C) cell lines in triplicate wells weremock-infected or infected with reovirus at MOI 70. After 72 hpi, cell viability wasquantified by trypan blue exclusion test. Mean ± SD, n=3,*P<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4478733&req=5

fig_002: Cell viability of canine solid tumor cell lines infected with reovirus. Canine MGT(A), osteosarcoma (B) and malignant melanoma (C) cell lines in triplicate wells weremock-infected or infected with reovirus at MOI 70. After 72 hpi, cell viability wasquantified by trypan blue exclusion test. Mean ± SD, n=3,*P<0.05.
Mentions: Reovirus-induced cytotoxicity: MTT assay quantifies the inhibition of cellproliferation through the reduction of total mitochondrial activity [32]. In order to examine the reovirus-induced cell death directly, allthe canine solid tumor cell lines were infected with reovirus at MOI 70, which is the titerof virus used for the cytotoxicity assay in mast cell tumor cell lines and lymphoma celllines in our previous report [9, 10], before trypan blue exclusion test was carried out to quantify theproportion of live and dead cells (Fig. 2Fig. 2.

Bottom Line: Reovirus has been proven to be a potent oncolytic virus in human medicine.The reovirus-induced cell death occurred via the activation of caspase 3.However, Ras activation was not related to the reovirus-susceptibility in canine solid tumor cell lines, which was similar to reports in canine mast cell tumor and canine lymphoma.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

ABSTRACT
Oncolytic virotherapy is a new strategy for cancer treatment for humans and dogs. Reovirus has been proven to be a potent oncolytic virus in human medicine. Our laboratory has previously reported that canine mast cell tumor and canine lymphoma were susceptible to reovirus. In this study, canine solid tumor cell lines (mammary gland tumor, osteosarcoma and malignant melanoma) were tested to determine their susceptibility towards reovirus. We demonstrated that reovirus induces more than 50% cell death in three canine mammary gland tumors and one canine malignant melanoma cell line. The reovirus-induced cell death occurred via the activation of caspase 3. Ras activation has been shown to be one of the important mechanisms of reovirus-susceptibility in human cancers. However, Ras activation was not related to the reovirus-susceptibility in canine solid tumor cell lines, which was similar to reports in canine mast cell tumor and canine lymphoma. The results of this study highly suggest that canine mammary gland tumor and canine malignant melanoma are also potential candidates for reovirus therapy in veterinary oncology.

No MeSH data available.


Related in: MedlinePlus